RESEARCH DOSSIER
Psychotherapy Comparative Effectiveness and Treatment Choice
Abstract. Psychotherapy comparative effectiveness evaluates relative benefits, harms, acceptability, durability, and practical utility of psychological interventions and alternative care strategies. This fundamental critical narrative monograph synthesizes historical comparative trials, randomized direct comparisons, pairwise and network meta-analyses, individual participant data studies, treatment-moderator research, patient preference evidence, and official guidance. Its core finding is that treatment superiority is inherently comparator-, disorder-, population-, outcome-, and time-dependent. For adult depression, structured psychotherapies often show meaningful effects relative to controls, whereas differences among active approaches tend to be smaller and more sensitive to study quality. Disorder-specific evidence can support more directed choices, particularly in PTSD. Patient preference, clinical complexity, treatment access, dropout, safety, and care sequences materially affect decision utility. Machine-assisted matching requires validated differential predictions and prospective clinical evaluation. The study reports no new patient data or novel pooled estimates and identifies priorities for rigorous direct trials, harm surveillance, durable outcomes, and external validation of precision selection.
Keywords: psychotherapy comparative effectiveness; treatment choice; psychological therapy; depression; cognitive behavioral therapy; interpersonal psychotherapy; trauma-focused psychotherapy; posttraumatic stress disorder; randomized controlled trials; network meta-analysis; individual participant data; comparative effectiveness research; patient preference; shared decision-making; treatment matching; treatment moderation; treatment safety; treatment dropout; digital psychotherapy; Artificial Era
The Scientific Object of Comparative Psychotherapy Research
Psychotherapy comparative effectiveness concerns the relative benefits, burdens, and consequences of choosing among psychological treatments and viable alternative care strategies for a specified clinical population. The research object is a treatment decision under uncertainty. Its fundamental question asks what would happen to comparable individuals if one accessible intervention rather than another were initiated, completed, or adapted over a defined period. The answer depends on diagnosis or presenting problem, outcome, time horizon, treatment setting, comparator, and patient priorities. A finding that psychotherapy improves symptoms compared with a waiting list does not establish superiority over another bona fide psychotherapy. The present study therefore treats comparative effectiveness as an explicitly contrast-dependent discipline rather than a league table of psychotherapy brands. This formulation is consistent with the contrasts evaluated in Barth (2013) and Cuijpers (2023).
The decision object has four interlocking levels. An intervention may be a theory-based treatment such as cognitive behavioral therapy (CBT), a specific technique such as behavioral activation or exposure, a treatment format such as group or internet delivery, or a care pathway that combines psychotherapy with medication and ongoing monitoring. The comparator may be another intervention, routine clinical care, a structured control, or delayed treatment. Outcomes may be symptom severity, remission, functioning, recovery, continued engagement, treatment burden, harms, or patient-defined improvement. Population and time specify whose outcome is being estimated and when. A precise comparison identifies these elements before presenting evidence; it also distinguishes treatment offered from treatment received and the effect of treatment assignment from the effect of completing a prescribed course.
This monograph organizes original comparative trials, network and conventional meta-analyses, individual participant data studies, decision-method research, and official clinical guidelines into a critical narrative synthesis. It has no prospectively registered systematic-search protocol, no newly gathered patient data, and no independently calculated pooled estimates. Numerical results are attributed to their originating studies, with scope and uncertainty preserved. The guiding propositions are that comparative benefit is context dependent, average estimates cannot automatically choose treatment for an individual, and evidence-informed choice must accommodate preference, access, safety, and the capacity to revise the plan. These propositions are examined as scientific claims and decision requirements rather than asserted as a novel validated clinical algorithm.
Definitions of Efficacy, Effectiveness, Acceptability, and Utility
Efficacy usually addresses whether an intervention produces a beneficial effect under conditions that support causal attribution, often through controlled randomization and protocolized delivery. Effectiveness asks how the intervention performs under ordinary service conditions involving heterogeneous patients, therapists, treatment adherence, interruptions, and resource constraints. The two inquiries overlap: randomized pragmatic trials can estimate real-world effects, while some tightly selected efficacy trials still recruit from routine clinics. The operative distinction is the target setting and decision, not a binary label attached to a trial. Evidence about efficacy can support clinical adoption, but its transport to a different population and care infrastructure requires additional arguments about patient selection, implementation, and measurement.
Acceptability is multidimensional. Trial retention, refusal after random assignment, stated preference, satisfaction, adverse events, and perceived burden supply different signals. A lower dropout rate can mean a treatment is easier to tolerate, but also can reflect shorter scheduled duration, access barriers, administrative discharge definitions, or missing follow-up. Utility integrates outcomes with the importance assigned to them and with cost, time, available clinicians, privacy, accessibility, and risk. A superior score on a symptom scale does not automatically establish the option with the greatest utility for a person who values sustained employment, autonomy, or avoiding a particular intervention exposure. Swift (2012) and Swift (2018) show why engagement and preference deserve distinct measurement.
Evidence-based treatment selection is therefore a conditional decision: which option offers the best expected balance for this person in this setting, given present evidence and legitimate uncertainty? The National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) operationalizes this perspective through shared decisions about recommended options, practical barriers, prior experience, and choice to decline or change treatment. The guideline is a jurisdiction-specific professional instrument, not a randomized demonstration that a single decision rule is universally optimal. The monograph uses such documents to connect empirical comparison with institutional practice without turning a research synthesis into individual medical advice.
The Historical Formation of Treatment Comparison
Formal comparative psychotherapy research developed alongside the experimental evaluation of psychological interventions and increasingly explicit distinctions between a therapeutic theory and a testable treatment protocol. Early traditions of psychoanalytic, behavioral, client-centered, and interpersonal treatment generated different accounts of change, but disagreements between theories did not themselves establish relative patient outcomes. A causal comparison required prespecified interventions, outcome measures, follow-up, suitable comparison conditions, and procedures reducing selection bias. As manuals and structured diagnoses became common in research, investigators could ask whether particular interventions outperformed alternative active treatments rather than judging success by theoretical coherence or clinical testimony alone.
The Elkin (1989) marked an important historical development. Its 250 participants were randomized across interpersonal psychotherapy, cognitive-behavioral treatment, imipramine with clinical management, and placebo with clinical management. The trial compared multiple credible approaches using common assessment and a specified 16-week treatment period. Its results have been debated partly because conclusions depend on patient severity, contrast, response definition, and statistical interpretation. The enduring contribution is the design of an explicit multiarm therapeutic comparison and the recognition that an apparently simple question about which treatment wins depends on details of the trial population.
Subsequent evidence synthesis transformed the field. Accumulating trials made it possible to compare outcome distributions across study populations, while network meta-analysis combined direct and eligible indirect comparisons to examine treatment families with few head-to-head trials. Barth (2013) exemplify this transition in adult depression. Later individual participant data synthesis and predictive modeling shifted attention from population means toward differential response and implementation. The historical trajectory is thus a progression of estimands and methods: demonstrating treatment effects, comparing active options, qualifying those comparisons by design, and investigating whether different people benefit from different choices.
The Logic of Counterfactual Treatment Choice
A relative treatment effect is defined through outcomes that could occur under alternative treatment assignments. For the same person at the same time, these alternatives cannot ordinarily be observed together. Random assignment creates groups in which observed outcome differences can estimate an average contrast if outcome ascertainment, missingness, deviations from assignment, and other biases are adequately managed. The contrast may be intention-to-treat, addressing the effect of assignment or offer, or a more restrictive adherence-related estimand. These are substantively different questions. A policy deciding which service to offer may need the intention-to-treat effect, whereas a mechanistic question about specific components may require a carefully justified different design.
The intervention description must support a meaningful counterfactual. Comparing a full course of individual CBT with a waitlist tests a compound difference involving professional attention, expectations, structure, duration, and treatment content. Comparing CBT with an equally credible structured intervention better narrows the difference between approaches, although the treatments may still vary in session frequency, therapist experience, and fidelity. Comparative trials cannot make every nonspecific feature identical. Researchers must therefore specify the components that are intentionally contrasted and which contextual influences remain part of the estimated treatment package. Cochrane. (2024). Cochrane handbook for systematic reviews of interventions (Version 6.5) (2024) provides a result-specific framework for considering these problems.
An effect is relative to a defined endpoint and follow-up. Response at the end of an intervention, recovery several months later, and prevention of recurrence over years are distinct causal targets. Differential dropout can shift which participants remain observable at later time points. If outcome measurement relies on self-report by people aware of their treatment assignment, detection and expectancy effects may complicate interpretation. Even when randomization is successful, the average result applies directly to the trial's enrolled population, intervention implementation, and observation period. Transport to a new care setting is a separate scientific inference requiring transparency about differences.
Comparator Architecture and the Meaning of Control Conditions
The choice of comparator strongly shapes an observed effect. A waiting list may control passage of time while leaving therapeutic attention and expectations unbalanced. Treatment as usual may include medication, counseling, monitoring, crisis response, or varying access to services, so its content must be documented rather than assumed. An attention control can balance contact yet differ in plausibility and expectations. An active treatment comparator creates a more demanding test of incremental effectiveness, but similarity of average outcomes does not establish that techniques are interchangeable across diagnoses, therapists, or individual priorities. The result of a contrast cannot be detached from the services actually received in each arm.
In the seven-treatment depression network, Barth (2013) found larger contrasts against waiting list than between active psychotherapies; the authors also observed sensitivity to study quality and sample size. This pattern explains why uncontrolled improvement and superiority to no immediate intervention should be interpreted separately from comparative superiority. It also cautions against pooling waitlist, usual care, psychological placebo, and active comparison arms under a single undifferentiated control label. A meta-analysis may require stratified contrasts, sensitivity analyses, or a model that explicitly represents these comparator distinctions.
A scientifically useful comparison table records diagnostic group, intervention content, comparator content, level of randomization, treatment duration, masking of outcome assessors, outcome time, analysis population, participant flow, and harms ascertainment. Such a table is an instrument for interpretation. It protects against treating two studies as identical merely because both mention CBT or supportive therapy. Comparability is a property demonstrated by methods and sample characteristics, not supplied by the similarity of treatment names.
Randomized Head-to-Head Trials and Practical Inference
Head-to-head trials randomly allocate participants among active interventions and directly estimate the difference relevant to a treatment choice. Their strength is close alignment between the study comparison and the decision. Their weakness is often limited power for modest differences or interactions: demonstrating that each intervention improves symptoms relative to baseline does not test whether they differ from each other. Likewise, an absence of statistical significance for the between-treatment contrast cannot prove clinical equivalence. Equivalence and noninferiority claims require their own prespecified margins, allocation strategies, adherence analyses, and safeguards against a poorly executed trial making treatments appear similar.
The Elkin (1989) depression study illustrates the importance of randomized multigroup assessment. The Foa (2005) PTSD trial compared prolonged exposure alone, prolonged exposure with added cognitive restructuring, and waiting list among female assault survivors with chronic PTSD. Both active conditions improved PTSD symptoms relative to the waitlist, while the added cognitive restructuring component did not improve outcomes in that particular trial. This result answers a component-level question for a specified sample and delivery setting. It does not prove that cognitive restructuring is unnecessary for every anxiety disorder or every configuration of psychotherapy.
Pragmatic effectiveness trials examine treatments in existing clinical systems and may better represent real service constraints. Yet broader eligibility and flexible delivery can increase variation in fidelity, cointerventions, and missingness. The ideal comparison depends on the decision. A health system choosing a scalable care package needs uptake, resource use, and functioning under ordinary conditions; a mechanism study may privilege manual fidelity and intermediate processes. Combining evidence requires attention to the question each study was designed to answer.
Pairwise Meta-Analysis and Evidence Heterogeneity
A pairwise meta-analysis estimates a defined contrast across eligible studies, often allowing true effects to vary between settings. Its interpretation depends on how studies define treatment, population, comparator, outcome, and observation time. Standardized mean differences can synthesize scales that nominally measure a common construct, but the resulting metric conceals clinically meaningful variation in baseline severity and scale reliability. A random-effects pooled estimate describes a distribution of potentially different effects; it is not a guarantee that each future clinic will reproduce the pooled average. Prediction intervals, where available, help communicate that uncertainty.
The Cuijpers (2023) synthesis of CBT for depression included 409 trials with 52,702 participants and examined CBT against controls, other psychotherapies, pharmacotherapy, and combined care. Its value is the ability to compare several contrast classes while assessing methodological trends. The authors reported a substantial average effect against control conditions; the modest estimated difference against other active psychotherapies was fragile in sensitivity analyses. Without distinguishing those comparator classes, a reader could misinterpret a large control contrast as a large margin of superiority over equally structured care.
Heterogeneity may reflect age, baseline severity, diagnostic definition, therapy format, therapist qualifications, control intensity, recruitment setting, study quality, or treatment duration. Subgroup analyses can explore such variation, but a significant subgroup difference is not a reliable patient-level predictor without an appropriate interaction design and replication. Small-study effects, publication bias, selective reporting, and outcome measurement differences can further distort estimates. A critical synthesis therefore reports the direction and methodological stability of findings instead of ranking approaches by isolated point estimates.
Network Meta-Analysis, Transitivity, and Consistency
Network meta-analysis connects treatments through a network of randomized comparisons. If A is compared with C in one set of trials and B with C in another, an indirect estimate of A versus B may be possible. This procedure rests on transitivity: the trials should be sufficiently comparable in distributions of relevant effect modifiers that the indirect comparison has scientific meaning. Consistency is the agreement between direct and indirect evidence where both exist. A sophisticated statistical model cannot rescue an indirect comparison linking systematically different populations, treatment eras, control intensities, or outcome definitions.
In adult depression, Barth (2013) synthesized 198 studies and 15,118 patients across seven psychotherapy approaches. Relative average differences were generally absent to small, with a reported contrast favoring interpersonal therapy over supportive therapy, alongside limitations from study quality and sample size. Network results must be interpreted with attention to treatment class definitions and confidence in the evidence. The network's existence expands the number of contrasts that can be estimated; it does not transform sparse indirect evidence into a definitive clinical hierarchy.
Treatment rankings are particularly vulnerable to overinterpretation. A high probability of being ranked first can coexist with little evidence of a clinically important difference from alternatives, especially where confidence intervals are broad. One must inspect absolute and relative effects, heterogeneity, evidence certainty, safety, treatment burden, and the decision comparator. For a therapy to become the preferred option, its advantages must matter for the population and outcomes under consideration. Research syntheses should publish sufficient details to permit examination of network geometry, indirectness, comparison-specific risk of bias, and plausible inconsistency.
Individual Participant Data and the Limits of Ecological Moderators
Individual participant data (IPD) meta-analysis combines appropriately harmonized person-level observations from multiple trials. Its promise is to evaluate treatment interactions and differential response while reducing some ecological fallacies inherent in trial-level subgroup comparisons. The availability of IPD depends on data access, compatible instruments, and consistent follow-up. Studies absent from the IPD pool may differ systematically from participating trials; harmonization can introduce its own assumptions. A patient-level predictive analysis should therefore report the source trials, missing variables, data completeness, external validity, and validation strategy.
Karyotaki (2017) examined self-guided internet CBT for depressive symptoms using individual participant data. Karyotaki (2021) later used an individual participant data network approach to evaluate guided and unguided internet CBT for depression. These projects show how methodological questions become more granular: whether treatment delivery and support differ in effect, which outcomes are preserved over time, and whether participant-level characteristics meaningfully change expected benefit. The findings cannot be transferred wholesale to every digital psychotherapy platform because programs, guidance, recruitment, and populations differ.
A recurrent problem is confusing prediction of outcome with prediction of comparative treatment advantage. Severity, motivation, or comorbidity may forecast poorer overall prognosis under both treatments without identifying which treatment is better. A moderator useful for selection must predict a treatment-by-characteristic interaction, preferably in external data. The absence of a robust interaction may be more informative for policy than a complex but unvalidated matching model.
Effect Sizes, Clinical Importance, and Reliable Change
Standardized effect sizes summarize differences in outcome distributions using a common statistical unit. Their magnitude depends on population variability, instrument, time point, and comparator. A small average standardized difference can have substantial implications at scale, yet cannot be translated directly into an individual's probability of remission without additional assumptions and baseline risks. Odds ratios and risk ratios have different properties from mean differences; remission and symptom change also answer different questions. Methodological care requires expressing outcomes in forms clinicians and patients can interpret while preserving uncertainty.
Jacobson (1991) developed a framework for clinically significant and statistically reliable individual change. Their proposal highlights that a change score must be distinguished from instrument error and from a meaningful movement in functioning. This measurement tradition remains important because group-average advantages can coexist with deteriorating individuals, nonresponders, and people whose important life outcomes improve despite limited movement on one symptom scale. The reliable-change index is a statistical method requiring adequate reliability and appropriate distributional assumptions, rather than an automatic clinical judgment.
A good comparative report states the exact outcome, its direction, scale, measurement schedule, missing-data method, and clinical context. Where available, it includes absolute remission or response rates and uncertainty intervals, as well as adverse or unwanted outcomes. It separates outcomes specified before the trial from those selected post hoc. These practices make treatment comparisons usable without converting every numerical difference into a categorical recommendation.
Depression Evidence Across Psychotherapy Families
Depression is among the most extensively researched indications for psychological treatment. Cognitive behavioral, interpersonal, problem-solving, behavioral activation, psychodynamic, and other structured approaches have been studied in randomized designs, although the number and quality of trials differ substantially across approaches. Barth (2013) reported broadly similar effects among several active psychotherapy families in their network, while recognizing individual contrasts and evidence limitations. Similarity of averages is best understood as a statement about the available comparative studies, not a claim that these therapies share identical theory, mechanism, cost, patient experience, or suitability for every presentation.
The Cuijpers (2023) reported a small CBT advantage relative to other psychotherapies, estimated at g = 0.06 with a 95% confidence interval from 0 to 0.12, and found that this difference became nonsignificant in most sensitivity analyses. The same review estimated g = 0.79 (95% CI 0.70–0.89) against control conditions. These findings cannot be summarized accurately by saying either that all approaches are interchangeable or that the numerically leading therapy is categorically superior. The comparator distinction and robustness checks determine what the evidence supports.
The World Health Organization. (2023). Brief (2023) includes behavioral activation, brief psychodynamic therapy, CBT, interpersonal therapy, problem-solving therapy, and third-wave approaches for moderate-to-severe depression. This is a service-level synthesis with stated recommendation strength and certainty, not direct confirmation of the relative advantage of every pair. The research question for CPP-21 is how to choose among legitimate evidence-supported options given relative outcomes, burden, availability, and person-specific goals.
The Role of Baseline Severity and Clinical Heterogeneity
Initial symptom severity shapes prognosis, available treatment options, and the interpretation of absolute improvement. It can also be associated with the magnitude of the contrast against a control condition. Cuijpers (2026) assessed baseline depression severity at the study level in 387 randomized trials involving 47,315 participants. Their meta-regression found an association between greater baseline severity and larger psychotherapy effects versus controls, although sensitivity analyses did not agree uniformly. This is evidence about between-study associations, with recognized limits for individual decision-making.
The causal question relevant to therapy choice is often whether severity changes the relative advantage of therapy A over therapy B, rather than whether more severely affected groups show larger benefits compared with control. These are different interactions. Study-level associations may reflect recruitment policies, measurement range, intervention intensity, co-occurring conditions, or comparator behavior. Even a replicated severity-by-treatment effect would require sufficient overlap in the characteristics of the populations receiving each option. A decision system should avoid converting meta-regression into a deterministic personalized recommendation.
Clinical presentations also vary within diagnostic labels. Recurrent depression, anxiety symptoms, interpersonal strain, trauma exposure, physical illness, and ongoing socioeconomic stress may affect engagement and the goals of treatment. Heterogeneity therefore belongs in every phase of research: selecting a clinically coherent population, specifying primary outcomes, evaluating treatment adherence, examining follow-up, and describing who was missing from the evidence. The National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) addresses these dimensions through assessment and shared planning, while remaining tied to its jurisdictional service framework.
Psychotherapy, Pharmacotherapy, and Combined Strategies
For depression, psychotherapy choices often occur alongside medication choices rather than within an isolated menu of talk therapies. A valid comparison distinguishes acute symptom response, functioning, recurrence, adverse effects, discontinuation, care preferences, and the burdens of combined delivery. Cuijpers (2020) used network meta-analysis to examine psychotherapies, pharmacotherapies, and their combinations in adult depression. Cuijpers (2021) specifically studied psychological and pharmacological strategies in primary care. Their differing populations and comparison structures underscore the need to resist direct transfer of a combined-treatment effect across all settings.
The pharmacotherapy evidence has its own research architecture. For example, Cipriani (2018) synthesized randomized trials comparing antidepressants for acute adult major depression, a different network and question from comparison of psychological interventions. A cross-modal choice must bring these evidence families together without assuming common outcomes, follow-up durations, participants, or acceptability definitions. Medication-specific contraindications and regulatory details belong to pharmacologic and clinical evaluation, not to an unsourced broad claim that one therapy form is harmless or universally preferable.
The National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) presents different treatment options for less severe and more severe depression, incorporates preference and shared decisions, and discusses changes when response is limited. Its structure illustrates an important principle: a treatment policy contains pathways for assessment, initial choice, monitoring, and subsequent revision. Comparative evidence must be interpreted within the actual care sequence rather than as a permanent ranking decided at the first encounter.
Posttraumatic Stress Disorder and Disorder-Specific Advantages
General statements that psychotherapies have similar average effects cannot erase condition-specific evidence. In posttraumatic stress disorder, research has centered on trauma-focused interventions such as prolonged exposure (PE), cognitive processing therapy (CPT), and eye movement desensitization and reprocessing (EMDR). The U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/ (2023) gives strong recommendations for these individually delivered treatments and for prioritizing them over medication in its stated PTSD population. The guideline distinguishes the certainty and recommendation strength assigned to individual interventions, with more limited evidence for several alternatives.
The Foa (2005) randomized comparison of PE, PE combined with cognitive restructuring, and waiting list offers a concrete example of component comparison rather than generic brand competition. The trial's female assault-survivor sample, session structure, and follow-up schedule matter. A conclusion that an added component did not improve outcomes in this design should remain tied to that design. Trials for military and civilian PTSD populations may differ in trauma histories, comorbidity, care context, and outcome assessor methods. Such differences are central to evidence transport.
Guideline recommendations also depend on evidence of harms and feasibility, practitioner training, and the population targeted by a recommendation. A comparison of PTSD treatments must not silently borrow average effect sizes from general depression networks or treat psychotherapy labels as identical across disorders. In practice, research-informed choice incorporates safety and access considerations and recognizes that patient participation in decisions is itself part of responsible care. This monograph describes guideline reasoning rather than prescribing treatment for a particular patient.
Anxiety Disorders and the Specificity of Exposure
The anxiety-disorder field contains diverse diagnostic populations, including panic disorder, social anxiety disorder, generalized anxiety disorder, and specific phobias. Although CBT is a broad family, its active elements may vary substantially across these problems. Exposure-based procedures target avoidance, conditioned fear, expectancy, and learning in ways that are not interchangeable with generic supportive counseling or with every cognitive intervention. Consequently, the term CBT alone is an inadequate treatment descriptor for a cross-disorder comparative claim. A rigorous review records protocol elements, session structure, outcome measures, and the diagnostic presentation studied.
Hofmann (2008) examined randomized placebo-controlled CBT trials across adult anxiety disorders. Such analyses establish efficacy under a specified placebo-controlled comparison, while head-to-head effectiveness questions require further examination of other active interventions and differential burden. A broad anxiety meta-analysis should identify which diagnoses contribute to each pooled estimate rather than extrapolating from one high-volume indication to all of them. For conditions in which a particular technique has a distinct evidence base, treatment choice may be more constrained than in an undifferentiated depression comparison.
Different anxiety outcomes also matter. Symptom ratings, avoidance behavior, daily functioning, panic attacks, clinically meaningful remission, and persistence at follow-up may diverge. Assessment settings influence observed responses; self-report and behavioral tasks can tell different stories. Treatment burden—including distress during exposure, attendance requirements, and access to trained providers—belongs in an honest comparison, along with the evidence that difficult sessions sometimes accompany clinically beneficial treatment. Unwanted experiences require direct measurement rather than assumption.
Age, Development, and Family Context
Comparative estimates from adult trials do not directly determine treatment choices for children, adolescents, or older adults. Developmental stage changes the organization of consent and assent, social support, school and family roles, symptom expression, cognitive demands, and the consequences of interrupted care. Trials in younger populations often involve parents, guardians, schools, or services that become components of the treatment package. A therapy with comparable symptom effects in adults may differ in feasibility or outcome significance when administered through a family or school system. Clinical guidelines should therefore be read within their explicitly stated age scope.
Developmental comparisons also require care in measurement. Two scales intended to represent depression or anxiety at different ages may not possess equivalent validity or sensitivity to change. Follow-up during a period of rapid development can reflect maturation, contextual transition, and changes in support as well as the intervention. For older adults, chronic illness, sensory or cognitive limitations, care dependence, and barriers to travel may influence which treatment formats are accessible. These are reasons to investigate population-specific effectiveness and intervention adaptation, not to substitute stereotypes for trial evidence.
A research program capable of informing treatment choice across the life course would report age ranges precisely, compare developmentally valid outcomes, describe family involvement, and evaluate both benefit and burden over meaningful periods. It would also include populations typically excluded by restrictive eligibility criteria. The absence of such evidence in a specific contrast should be recorded as uncertainty rather than filled with extrapolated claims from other age groups.
Comorbidity, Complexity, and Treatment Sequencing
Randomized psychotherapy trials frequently manage eligibility to improve interpretability, sometimes excluding psychosis, active substance problems, acute risk, serious medical illness, or unstable treatment. Those choices alter the target population. Routine clinical care often involves overlapping conditions, prior unsuccessful treatments, changing medication, housing instability, and limited access to specialty clinicians. Treatment comparisons based on narrow trials can be helpful for a component decision but may have limited external validity for complex service populations. The strength of inference depends on the clinical relevance of exclusion criteria and the extent of empirical replication in broader samples.
Complexity also makes sequencing a distinct scientific problem. A patient may begin a lower-intensity intervention, be reviewed, step into structured psychotherapy, combine interventions, or switch after inadequate response. The best first-line average effect may differ from the best overall strategy across several decision points. Estimating such dynamic treatment regimes requires trials or credible longitudinal causal methods that account for outcomes and choices at each stage. A simple comparison of end-of-treatment scores from first-line trials cannot determine the optimal sequence of interventions.
National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) explicitly discusses monitoring, further-line options, and revisiting diagnosis and barriers when response is limited. In research terms this illustrates the difference between a static treatment effect and an adaptive care policy. It also highlights why a full comparative dossier must consider sustained engagement, treatment change, adverse effects, and patient autonomy as outcomes of care rather than secondary administrative details.
Digital, Guided, and Unguided Treatment Formats
Psychological treatment is increasingly delivered through video sessions, structured web programs, asynchronous modules, and supported digital systems. A digital intervention is not a single treatment category: the program may use CBT procedures, behavioral activation, problem-solving, psychoeducation, or other elements, and support may be supplied by a clinician, coach, or automated interface. The contrast of interest can concern content, human guidance, delivery medium, time, location, cost, or a combination. Simply labeling a program internet CBT can obscure clinically consequential variation in these dimensions.
Karyotaki (2017) studied self-guided internet CBT for depressive symptoms using individual participant data. The later Karyotaki (2021) network synthesis explicitly compared guided and unguided formats while analyzing participant-level outcomes. Their methods create a basis for questions about support intensity, adherence, follow-up, and accessibility. Findings tied to specific programs and trial-era technologies require re-evaluation when a new platform changes content, clinician involvement, privacy architecture, or the population reached.
Digital access can reduce travel burdens yet introduce new barriers through disability, connectivity, language, private space, digital literacy, or security risks. Interventions that perform well among motivated volunteers recruited online may not have equivalent reach or effect in under-resourced clinics. Comparative effectiveness thus includes the denominator of eligible and actually engaged patients, along with the risk of excluding people through design. A scalable format earns public-health value when it preserves meaningful outcomes and reaches people who would otherwise lack suitable care.
Individual, Group, and Service-Level Delivery
Treatment format changes more than scheduling. Individual psychotherapy allows a different degree of personalization and privacy from group therapy, whereas group delivery adds peer interaction and may lower the amount of clinician time per participant. Structured short interventions and blended care can expand reach but also alter continuity, fidelity, and the opportunities to respond to risk or clinical deterioration. A comparison of modalities is therefore a comparison of treatment packages and service systems. It should specify whether the estimand concerns an individual's received dose or the effect of offering a program to a defined clinic population.
Cost-effectiveness requires jointly analyzing health outcomes and resource use rather than declaring that the cheaper delivery mode is preferable. A group intervention with lower per-session cost may require recruitment, coordination, suitable group composition, and staff capacity. A digital program can have low marginal cost but substantial costs for development, security, clinician oversight, accessibility, and user support. Different health systems also assign different costs to patient travel, lost work, and waiting time. Studies should state their perspective and time horizon before making economic conclusions.
Service capacity creates a crucial decision constraint: a treatment that is theoretically preferred but unavailable for many months may yield a different real-world result than a timely effective alternative. Choice is partly determined by institutional access, clinician availability, referral pathways, and geographic distribution. Evidence syntheses that exclude these dimensions remain valuable for causal efficacy but incomplete for a system-wide decision.
Treatment Intensity, Duration, and Dose
The concept of psychotherapy dose usually refers to some combination of sessions, contact hours, completion, homework or practice, and total time in a program. These dimensions should be distinguished: eight long individual sessions are not necessarily equivalent to eight brief guided digital modules. Session count may be a post-randomization variable because people who improve rapidly, become discouraged, or face practical obstacles can stop early. Simple correlations between the number of attended sessions and outcome therefore cannot establish the causal effect of dose.
A treatment-choice study should describe the intended schedule and the distribution of actual exposure, and should estimate outcomes for people assigned to each package before conducting adherence-sensitive supplementary analyses. It should also consider the clinical burden of intensity, including missed work, fatigue, transportation, or distress associated with particular procedures. Lower intensity may be valuable when benefits are adequate and treatment can be stepped up after monitoring, but this proposition requires prospective comparison under a defined service policy.
Duration interacts with time-to-benefit, relapse prevention, and patient priorities. Early relief and durable recovery may rank interventions differently. Research should preserve these distinctions rather than collapsing a course of care into a single end-point effect.
Client Preference and Preference Accommodation
Patient preference can concern modality, treatment rationale, expected activities, clinician characteristics, schedule, cultural framing, privacy, medication use, and the intensity of distress expected during therapy. Preference has ethical significance because informed choice is part of legitimate clinical decision-making, but it also poses empirical questions: does receiving a preferred treatment improve engagement or clinical outcome, and does preference interact with the relative effects of interventions? These questions require different designs. Observational choice can confound preference with resources or prognosis, while randomized preference designs can clarify some of the tradeoffs.
McHugh (2013) reviewed studies of psychological versus pharmacologic treatment preferences and reported that approximately three quarters of participants preferred psychological treatment in the studied samples. That pooled preference describes the sampled settings and conditions, not a universal rate for every country or disorder. Swift (2018) synthesized 53 studies with more than 16,000 clients and reported an association between accommodating preference and reduced dropout and more favorable outcomes. Effects varied by study features; they cannot be assumed causal in every implementation.
In treatment choice, preferences should be elicited with intelligible descriptions of active procedures, likely burdens, uncertainties, and available alternatives. Strong prior preferences may alter willingness to begin an intervention, making a nominally superior therapy an inferior practical offer when uptake is low. The scientific question extends beyond asking what patients choose: it includes how preference is formed, whether information corrects misunderstanding, and whether accommodation changes outcomes after accounting for selection.
Therapeutic Alliance and Relational Processes
Therapeutic alliance commonly refers to collaborative agreement on goals and tasks together with the bond supporting therapeutic work. Its empirical relevance spans many schools. Flückiger (2018) synthesized 295 independent studies involving more than 30,000 patients and found a positive association between alliance and psychotherapy outcome; the reported aggregate face-to-face correlation was approximately r = .278. That is evidence of robust association across diverse settings, but its causal decomposition remains difficult because early improvement can influence perceived alliance, and shared reporting methods can create additional correlations.
Alliance research complicates simple brand comparisons. The same manualized treatment may yield different experiences depending on therapist skill, responsiveness, and the match between tasks and patient expectations. Alliance is also dynamically constructed: it may improve as symptoms improve, deteriorate during conflict, or be repaired through negotiation. A baseline label of therapy type says little about these trajectories. Outcome comparisons therefore require attention to the quality of treatment delivery, while avoiding the circular inference that a successful therapy must have been delivered with good alliance.
Research designs combining repeated alliance measurement, prior symptom adjustment, randomization of process interventions, and therapist-level modeling can improve causal interpretation. Yet a correlation should not be translated into a claim that strengthening the alliance by a fixed amount will necessarily generate a corresponding outcome gain. Mechanism identification remains a distinct research question from comparative effectiveness, even when relational factors are essential to service quality.
Therapist Effects, Competence, and Fidelity
Psychotherapy is delivered through people and organizational arrangements. Therapist expertise, training, case load, supervision, allegiance to a school, cultural responsiveness, and skill in adapting an approach can influence the effectiveness of a particular treatment package. When therapists are nested within a study arm, treatment and therapist effects may be partly confounded. A trial with unusually experienced clinicians in one intervention can exaggerate the apparent superiority of that modality. Multi-therapist and multi-site designs reduce some of this risk but also require adequate statistical modeling.
Treatment fidelity has several dimensions: adherence to prespecified elements, competence in delivery, and differentiation from comparator treatment. High adherence does not necessarily imply high therapeutic quality, especially when rigid protocol use conflicts with a patient's emergent needs. Conversely, undocumented adaptation can prevent readers from determining what treatment was actually studied. Comparative effectiveness thus benefits from fidelity measures, credible training standards, independent ratings, and explicit descriptions of permissible adjustment. Study reports should make therapist qualifications and treatment allocation transparent.
Therapist and treatment effects may interact. Some clinicians may be effective with several approaches, while others achieve better results when delivering a familiar protocol. A research program that seeks a stable therapy ranking must test whether the rank survives changes in therapist, clinic, supervision, and recruitment setting. Without that evidence, a therapy label alone underdescribes the true intervention.
Precision Treatment Selection and Predictive Models
Precision treatment selection tries to identify characteristics that change the expected difference between two or more treatments. A person can have a poor predicted outcome under every option yet still have a meaningful advantage under one of them. Conversely, a high predicted response under one therapy does not prove that it is preferable to an alternative without estimating the second potential outcome. Treatment selection models therefore need differential treatment-effect estimation, comparison-specific calibration, and validation in new samples, rather than ordinary prognostic accuracy alone.
DeRubeis (2014) introduced the Personalized Advantage Index as a demonstration using data from a randomized comparison of treatments for depression. The method combined predictors to estimate an individual's relative benefit between treatments. Its historical importance is methodological: it made individualized comparative prediction explicit and testable. The demonstration's findings should not be interpreted as prospective proof that deploying a particular algorithm improves outcomes in routine clinics; external and prospective trials are required to establish actual decision benefit.
Models with many interactions are vulnerable to overfitting, leakage from outcome-derived variables, inadequate representation of minority populations, and performance deterioration after health-service change. Good validation separates derivation from evaluation, uses pretreatment features available at decision time, examines model calibration, and measures the effect of using recommendations in actual care. Prediction intervals and uncertainty should be presented in understandable terms. Where evidence is insufficient, a shared evidence-based choice can be preferable to a spurious machine-calculated ranking.
The Distinction Between Prognosis and Moderation
Prognostic variables predict outcomes without necessarily changing the difference between treatments. Moderators predict variation in a treatment contrast. This distinction is essential because many familiar clinical factors—baseline severity, previous episodes, social adversity, comorbidity, or early motivation—can plausibly forecast overall recovery while providing limited reliable evidence for choosing one evidence-supported psychotherapy over another. An interaction requires direct statistical evaluation, adequate sample size, and replication. A significant effect in a single small subgroup may easily reflect multiplicity or chance.
The 2026 study by Cuijpers (2026) is a useful example of correct scope. Its analysis related baseline severity at the study level to the effects of psychotherapy relative to control groups. Such a result informs expectations about effect estimates across trials, while leaving the individual-level therapy A versus therapy B question largely unresolved. The paper itself reports some sensitivity analyses inconsistent with the central association. The distinction between design levels prevents a tempting but unwarranted interpretation of a meta-regression as an individual therapy matching formula.
A careful treatment-selection study prespecifies candidate moderators, validates measurement reliability, limits unnecessary model complexity, and reports how an identified interaction changes absolute decision outcomes. It also examines whether moderator measurement imposes extra cost, stigmatizes patients, or uses information unavailable in under-resourced settings. The purpose of precision is to improve care decisions, and that claim demands prospective evidence of benefit, feasibility, and fairness.
Safety, Deterioration, and Negative Treatment Experiences
Psychotherapy can entail unwanted effects, emotional distress, increased symptoms, perceived invalidation, privacy concerns, damaged relationships, or clinical deterioration. Some distress may be an anticipated component of exposure-based work, while other experiences reflect adverse processes or failure to respond. Scientific evaluation must distinguish transient discomfort, foreseeable treatment burden, adverse events, reliable symptom deterioration, and events caused or plausibly contributed to by treatment. These categories cannot be collapsed into a reassuring assumption that psychological interventions have no harms.
Honkalampi (2025) systematically reviewed negative effects reporting in randomized psychotherapy and psychological-intervention trials. This evidence highlights an important methodological deficit: study reports do not always measure and classify harms with the same attention as intended benefits. Differential ascertainment is a threat to comparative safety conclusions. If one intervention reports every episode of worsening and another reports only serious adverse events, a simple count is misleading. Standardized adverse-event definitions and independent assessment improve interpretability.
Safety is a dynamic treatment-choice consideration. A service needs procedures to identify deterioration, emerging risk, inadequate response, and need for a different level of care. The National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) emphasizes monitoring for harms and suicidal ideation as part of treatment management. This monograph describes the evidence and the logic of monitoring but does not provide patient-specific treatment or crisis instructions. Clinical interpretation of individual risk requires qualified professionals working within applicable clinical protocols.
Longitudinal Outcomes, Recurrence, and Durability
Posttreatment improvement is a useful but incomplete endpoint. People may recover, relapse, switch care, begin medication, obtain additional psychotherapy, or experience new adversities after the initial course. Comparisons of durable effect must distinguish continued protection attributable to the original treatment from the consequences of subsequent care. Longitudinal studies should record cointerventions, treatment exposure, loss to follow-up, and changes in diagnostic criteria or outcome instrumentation. An effect measured at the end of treatment cannot be presumed constant over several years.
The Cuijpers (2023) CBT synthesis discussed follow-up in its depression evidence, while the National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) explicitly treats relapse prevention and continuation as separate decisions. This distinction matters for the comparison of psychotherapy with medication and their combinations: acute response, prevention of recurrence, and long-term tolerability are separate estimands, often supported by different study designs and data availability.
Long-term evaluation should include functioning, social participation, quality of life, patient-defined recovery, and adverse consequences in addition to diagnostic symptom scores. Missing follow-up can be particularly selective when relapse, dissatisfaction, or service disengagement occurs. A robust comparative research program predefines the follow-up interval and analyzes attrition transparently rather than relying only on participants who remained readily accessible.
Evidence Certainty and Guideline Translation
A clinical practice guideline integrates available studies with explicit judgments about quality, relevance, harms, preferences, costs, feasibility, and health-system objectives. Its recommendation is an evaluated decision under a defined scope, not the same object as a pooled treatment effect. Readers should examine the guideline's population, jurisdiction, publication and revision dates, method for reviewing evidence, and the strength assigned to each recommendation. High certainty that an intervention has a beneficial effect does not necessarily imply high certainty in every indirect comparison with another option.
The World Health Organization. (2023). Brief (2023), National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.), and U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/ (2023) show how policy judgments depend on disorder, resources, feasibility, and strength of evidence. They also illustrate why importing a recommendation from one condition into another is methodologically unsound. A guideline that strongly endorses specific trauma-focused treatments in PTSD does not imply the same hierarchy for depression or unrelated counseling objectives.
An editorial synthesis should distinguish statements originating in randomized comparative evidence from contextual recommendations originating in guideline deliberation. It should identify when a recommendation's certainty or evidence base is limited, and avoid claiming an entire professional consensus where explicit disagreement or heterogeneity remains. Where regulatory or clinical content is consequential, qualified review is a separate editorial gate.
Accessibility, Equity, and Evidence Transport
Comparative treatment evidence is produced in particular cultures, languages, service systems, and research institutions. Trial participants may have the time, transportation, language fluency, and insurance or service access necessary to attend structured care. These selection conditions alter the population to whom a result generalizes. Racialized barriers, discrimination, disability inaccessibility, geographic disadvantage, financial insecurity, and immigration-related constraints can affect recruitment, engagement, and follow-up. A clinically effective intervention that is unavailable or inappropriate in practice cannot be evaluated solely through an idealized efficacy estimate.
Cultural responsiveness requires evaluating the fit of explanatory models, goals, language, family roles, trust, and therapeutic procedures. These factors may affect the acceptability of treatment and the meaning of common outcomes. Research should avoid assuming that a single identity variable is a stable treatment moderator; the causal conditions may lie in institution, neighborhood, clinician behavior, or available supports. Comparative studies benefit from transparent inclusion criteria, subgroup representation, translation procedures, and measurement-equivalence testing.
Evidence transport is most defensible when the target population and implementation conditions are explicitly described. Researchers can examine whether treatment differences remain when data are restricted to representative service samples, whether support requirements change feasibility, and whether disadvantaged groups are systematically lost from follow-up. In this sense, an equitable evidence base is a methodological requirement for credible population-level comparative effectiveness.
Cost, Capacity, and Population-Level Treatment Choice
Health systems allocate scarce professional time, clinic space, and financing across patients with different needs. The relevant population-level question may concern the consequences of expanding access to several effective treatments rather than choosing a single top-ranked therapy for everyone. A service can sometimes increase overall benefit through stepped care, group delivery, telehealth, task sharing, or streamlined referral, but each strategy requires its own evaluation of quality, reach, and safety. A low-cost intervention that is poorly completed may deliver less population benefit than a more intensive program; conversely, a highly effective intervention reaching very few people can leave substantial unmet need.
Cost-effectiveness combines resource use and health outcomes within an explicit perspective and time horizon. Clinician time, administrative coordination, patient travel, technology, training, follow-up, and adverse events may all matter. Researchers should avoid comparing unit prices without measuring effects or treating list price as the full cost of care. The World Health Organization. (2023). Brief (2023) illustrate the public-health relevance of scalable structured interventions, while leaving implementation-dependent cost questions to local evidence.
Decision thresholds may differ across systems, but the scientific task is stable: identify opportunity costs, record whose outcomes are valued, measure uptake and benefit, and report uncertainty. Ethical treatment choice at scale requires transparency about whose preferences are represented and whose access is constrained.
The Artificial Era and Computational Decision Support
The Artificial Era introduces new tools for organizing comparative psychotherapy evidence: machine-readable trial registries, literature retrieval, outcome prediction, decision aids, and adaptive digital service interfaces. Artificial systems can help expose mismatches between a proposed treatment claim and its underlying population, comparator, or evidence quality. They can also assist in explaining options in accessible language. Their usefulness must be judged by accuracy, calibration, transparency, privacy protection, and experimentally measured improvement in decisions. A plausible recommendation from an automated system is a generated proposition that still requires evidence and clinical governance.
Artificial cognition and decision support can reproduce the classic distinction between prognosis and moderation. A model trained on patients receiving a single treatment may predict response reliably and still be unable to compare the outcomes of alternative interventions. A system that retrieves a guideline and produces a ranking may omit a contraindication, access limitation, or uncertainty. Valid evaluation requires external testing, treatment contrast awareness, audit trails, clinician oversight for consequential choices, and clear separation of measured outcomes from model-generated hypotheses. DeRubeis (2014) illustrates how differential prediction is framed as a scientific problem rather than an unconstrained recommendation task.
Within the intellectual horizon of Artificial Era · From Homo to Artificial, comparative treatment choice becomes one setting in which Homo and Artificial participate in a shared information environment. Psychology examines human outcomes and agency; computational science examines model reliability and decision architecture; ethics examines authority and responsibility. This framing is an authorial interdisciplinary interpretation. It is distinct from empirically demonstrated treatment superiority and does not establish clinical efficacy for artificial systems without relevant trials.
Methodological Threats to Comparative Conclusions
The most influential methodological threats include selective study enrollment, inadequate allocation concealment, incomplete outcome ascertainment, unblinded subjective measurement, selective outcome reporting, trial allegiance, small samples, and heterogeneity in comparators. The inability to blind participants and therapists to many psychotherapy modalities makes careful outcome measurement and reporting particularly important. Cochrane. (2024). Cochrane handbook for systematic reviews of interventions (Version 6.5) (2024) evaluates risk of bias for a particular result rather than assigning an unqualified quality label to an entire clinical paper.
Synthesis-level threats add publication bias, duplicate cohorts, overlap among reviews, post hoc subgroup selection, poorly supported treatment taxonomy, and network intransitivity. A review reporting several statistically significant contrasts from many candidate analyses needs to disclose multiplicity and decision-relevant robustness. Page (2021) established PRISMA 2020 reporting expectations for systematic reviews. The present monograph does not claim to meet PRISMA as a conducted systematic review because it has not implemented a preregistered or reproducible comprehensive search and study-selection protocol.
Editorial evidence grading should distinguish original studies inspected directly from records assessed through available abstracts, and should never convert an abstract's general conclusion into fabricated detail about trial procedures or subgroup estimates. It should also document the source and date of guideline recommendations. These conditions are prerequisites for a responsible full technical release.
Contradictions, Uncertainty, and Interpretation
Comparative psychotherapy science sometimes appears contradictory because studies ask different questions. One review can find an intervention superior to waiting list, a second find little difference from another structured therapy, and a third identify a small advantage in a carefully defined population. All three can be simultaneously coherent. Apparent conflict should be resolved first by checking comparator, diagnosis, intervention definition, outcome, follow-up, and risk of bias. Where these match and results remain discordant, heterogeneity and uncertainty should be reported explicitly rather than resolved by rhetorical preference for a school.
Anxiety and PTSD also demonstrate the boundaries of a general psychotherapy comparison. Active treatments can have similar mean effects in one depression network while disorder-specific guidelines strongly endorse particular techniques based on their own evidence. The synthesis should preserve both the general pattern and the disorder-specific recommendation, without forcing them into a universal treatment ranking. The same reasoning applies to comparisons with medication, guided digital care, and long-term relapse-prevention strategies.
Scientific uncertainty is often structural: even a well-powered treatment trial does not reveal the counterfactual outcome of each individual, and a complex matching algorithm can be accurate on average yet fail under distribution change. Responsible decision support communicates this limitation while offering the strongest evidence-supported comparison available.
An Evidence-Linked Framework for Treatment Comparison
A defensible scientific comparison can be organized into a sequence of questions. First establish the specific problem, age group, clinical complexity, risk, and goals. Second enumerate treatments that are genuinely feasible and evidence-supported in the relevant jurisdiction. Third match each candidate to studies with comparable populations, controls, endpoints, and treatment duration. Fourth evaluate the magnitude and certainty of expected benefit alongside risks, burdens, and probable engagement. Fifth elicit preferences after giving a comprehensible description of alternatives. Sixth record an agreed monitoring and review process, with criteria for reassessment. These are analytic requirements, not a validated bedside score or independent clinical guideline.
The decision can be represented conceptually as a comparison of expected multidimensional outcomes under alternative feasible policies, conditional on patient characteristics and system constraints. The utility weights remain partly value judgments, and the predicted outcomes carry statistical uncertainty. The National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30 (n.d.) supplies an institutional example of evidence-informed assessment, preference-sensitive choice, monitoring, and further-line revision. The U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/ (2023) demonstrates that the candidate set and evidence hierarchy change across clinical indications.
Future work must test the usefulness of such decision structures by evaluating actual changes in patient-centered outcomes and documenting any adverse effects of decision support. The methodological aim is transparent reasoning that can be corrected as new evidence arrives.
Research Priorities and the Next Generation of Comparative Evidence
The highest-value future evidence will often come from adequately powered direct comparisons addressing decisions clinicians and patients actually face: alternative active interventions, differential follow-up, treatment sequencing, and care adapted to incomplete response. Trials should report treatment content, fidelity, therapist training, costs, and acceptability, alongside prespecified symptom and functioning endpoints. Studies of psychological treatment safety should standardize adverse-event definitions and collect unwanted outcomes prospectively. Longer follow-up needs transparent handling of dropout and subsequent care.
Precision research requires reliable treatment moderators, predecision predictors, external validation, prospective evaluation of recommendation algorithms, and analysis of fairness across underrepresented populations. Individual participant data networks are especially promising when instruments are harmonized and missingness is investigated, but data pooling cannot repair a fundamentally unrepresentative set of trials. For digital and artificial delivery, investigators must test program versions and support arrangements actually deployed rather than borrowing effectiveness from a superficially similar historical technology.
A mature evidence infrastructure would allow researchers to track outcome definitions, comparator intensity, trial provenance, published revisions, retractions, and guideline changes over time. Its central achievement would be stronger comparability across studies and more honest translation to decisions. The field advances when scientific claims become specific enough to test, replicate, qualify, and revise.
Conclusion
The evidence on psychotherapy comparative effectiveness supports a disciplined form of treatment choice. Across adult depression trials, multiple structured psychotherapies show beneficial effects, and differences between active approaches are often smaller and more sensitive to design than differences from waiting-list or other control conditions. This general pattern coexists with diagnosis-specific evidence, as illustrated by trauma-focused interventions for PTSD. Comparisons with medication, combinations, digital formats, and service pathways add further dimensions of benefit, burden, and uncertainty. No universal ranking can answer all these distinct questions.
Scientific choice requires the alignment of research with a precisely defined decision: who is being treated, for which problem, with what feasible alternatives, under which service conditions, and toward which outcomes over which period. Rigorous randomized trials and evidence syntheses supply average estimates; individual participant data and prospective predictive studies examine heterogeneity; shared decision-making incorporates preferences and constraints; repeated measurement reveals when a strategy should be reconsidered. Evidence certainty and clinical safety remain explicit rather than assumed.
The enduring conclusion is that comparative effectiveness is a research architecture for justified decisions under uncertainty. Its standards are accurate contrasts, credible causal inference, patient-centered outcomes, source transparency, and ethically governed translation. The continuing scientific agenda concerns external validity, durable outcomes, harms, prospective treatment matching, and the consequences of bringing artificial decision support into psychological care.
References
- Barth, J., Munder, T., Gerger, H., Nüesch, E., Trelle, S., Znoj, H., Jüni, P., & Cuijpers, P. (2013). Comparative efficacy of seven psychotherapeutic interventions for patients with depression: A network meta-analysis. PLOS Medicine, 10(5), e1001454. https://doi.org/10.1371/journal.pmed.1001454
- Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
- Cochrane. (2024). Cochrane handbook for systematic reviews of interventions (Version 6.5), Chapter 8: Assessing risk of bias in a randomized trial. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08
- Cuijpers, P., Harrer, M., Miguel, C., Karyotaki, E., & Papola, D. (2026). Does baseline severity interact with the effects of psychotherapy for depression? A meta-analytic review. Journal of Affective Disorders, 399, 121106. https://doi.org/10.1016/j.jad.2025.121106
- Cuijpers, P., Miguel, C., Harrer, M., Plessen, C. Y., Ciharova, M., Ebert, D., & Karyotaki, E. (2023). Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry, 22(1), 105–115. https://doi.org/10.1002/wps.21069
- Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92–107. https://doi.org/10.1002/wps.20701
- Cuijpers, P., Oud, M., Karyotaki, E., Noma, H., Quero, S., Cipriani, A., Arroll, B., & Furukawa, T. A. (2021). Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: A network meta-analysis. Annals of Family Medicine, 19(3), 262–270. https://doi.org/10.1370/afm.2676
- DeRubeis, R. J., Cohen, Z. D., Forand, N. R., Fournier, J. C., Gelfand, L. A., & Lorenzo-Luaces, L. (2014). The personalized advantage index: Translating research on prediction into individualized treatment recommendations. A demonstration. PLOS ONE, 9(1), e83875. https://doi.org/10.1371/journal.pone.0083875
- Elkin, I., Shea, M. T., Watkins, J. T., Imber, S. D., Sotsky, S. M., Collins, J. F., Glass, D. R., Pilkonis, P. A., Leber, W. R., Docherty, J. P., Fiester, S. J., & Parloff, M. B. (1989). National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Archives of General Psychiatry, 46(11), 971–982. https://doi.org/10.1001/archpsyc.1989.01810110013002
- Flückiger, C., Del Re, A. C., Wampold, B. E., & Horvath, A. O. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. Psychotherapy, 55(4), 316–340. https://doi.org/10.1037/pst0000172
- Foa, E. B., Hembree, E. A., Cahill, S. P., Rauch, S. A. M., Riggs, D. S., Feeny, N. C., & Yadin, E. (2005). Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: Outcome at academic and community clinics. Journal of Consulting and Clinical Psychology, 73(5), 953–964. https://doi.org/10.1037/0022-006X.73.5.953
- Hofmann, S. G., & Smits, J. A. J. (2008). Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. The Journal of Clinical Psychiatry, 69(4), 621–632. https://doi.org/10.4088/jcp.v69n0415
- Honkalampi, K., Urhonen, H.-R., & Virtanen, M. (2025). Negative effects in randomized controlled trials of psychotherapies and psychological interventions: A systematic review. Psychotherapy Research, 35(1), 100–111. https://doi.org/10.1080/10503307.2024.2301972
- Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology, 59(1), 12–19. https://doi.org/10.1037/0022-006X.59.1.12
- Karyotaki, E., Efthimiou, O., Miguel, C., Maas Genannt Bermpohl, F., Furukawa, T. A., Cuijpers, P., & the Individual Patient Data Meta-Analyses for Depression (IPDMA-DE) Collaboration. (2021). Internet-based cognitive behavioral therapy for depression: A systematic review and individual patient data network meta-analysis. JAMA Psychiatry, 78(4), 361–371. https://doi.org/10.1001/jamapsychiatry.2020.4364
- Karyotaki, E., Riper, H., Twisk, J., Hoogendoorn, A., Kleiboer, A., Mira, A., Mackinnon, A., Meyer, B., Botella, C., Littlewood, E., Andersson, G., Christensen, H., Klein, J. P., Schröder, J., Bretón-López, J., Scheider, J., Griffiths, K., Farrer, L., Huibers, M. J. H.,. Cuijpers, P. (2017). Efficacy of self-guided internet-based cognitive behavioral therapy in the treatment of depressive symptoms: A meta-analysis of individual participant data. JAMA Psychiatry, 74(4), 351–359. https://doi.org/10.1001/jamapsychiatry.2017.0044
- McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: A meta-analytic review. Journal of Clinical Psychiatry, 74(6), 595–602. https://doi.org/10.4088/JCP.12r07757
- National Institute for Health and Care Excellence. (2022; recommendations last reviewed January 30, 2026). Depression in adults: Treatment and management (NICE Guideline NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S.,. Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
- Swift, J. K., Callahan, J. L., Cooper, M., & Parkin, S. R. (2018). The impact of accommodating client preference in psychotherapy: A meta-analysis. Journal of Clinical Psychology, 74(11), 1924–1937. https://doi.org/10.1002/jclp.22680
- Swift, J. K., & Greenberg, R. P. (2012). Premature discontinuation in adult psychotherapy: A meta-analysis. Journal of Consulting and Clinical Psychology, 80(4), 547–559. https://doi.org/10.1037/a0028226
- U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/
- World Health Organization. (2023). Brief, structured psychological treatment: mhGAP evidence centre recommendation for depression. https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre/depression/brief-structured-psychological-treatment